ARTICLE

RESPONDING TO THE HITCH IN FIGHTING CANDIDA ALBICANS THROUGH NANOMEDICINE

  1. HOME
  2. ARTICLE

06 Pages : 55-60

http://dx.doi.org/10.31703/gpsr.2021(VI-I).06      10.31703/gpsr.2021(VI-I).06      Published : Jun 2021

Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine

Abstract

    Candida albicans, as an opportunistic pathogen has been closely associated with both mucosal and deep tissue life-threatening infections in patients being immuno compromised or hospitalized for some grave underlying ailment. Antifungal therapy so far has not been much successful to reduce mortality and morbidity associated with candidiasis. Furthermore the complete eradication of fungal infection requires long-term treatment that may continue for a month, making patients more vulnerable to adverse effects. The emergence of Candida albicans resistant strains against commonly prescribed antifungals is also a major area of concern demandingimmediate consideration. Researchers are continuously investigating newer approaches to counter the deficiencies in conventional treatment strategies. One of these approaches involves the use of nanotechnology to overcome challenges associated with anti fungal therapy. This review focuses on various means that have been employed to effectively counter puzzles supplementary to Candida albicans by use of nano medicines.

    Nanomedicine, Candida Albicans, Antifungal Therapy, Long-term Treatment, Drug Resistance

    (1) Salman Arshad
    Department of Pharmacy, The University of Lahore, Lahore, Punjab, Pakistan
    (2) Rabia Arshad Khan
    Assistant Professor, Department of Pharmacy, The University of Lahore, Lahore, Punjab, Pakistan
    (3) Haleema Sadia
    Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Punjab, Pakistan.
Fulltext PDF

References

  • Joon, K. (2011).Candida albicans: A major human pathogen. The Journal of Microbiology,
  • Yuvraj, S. D. (2010). Kamta Prasad Namdeo, Oral Candidiasis: A Review. International Journal of Pharmacy and Pharmaceutical Sciences,
  • Donlan, R. M., (2002). Biofilms: Microbial Life on Surfaces. Emerging Infectious Diseases, 8(9), p. 881-890.
  • Pfaller, M. A., & Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clinical Microbiology Reviews, 20(1), 133-163.
  • Sahnoun, Z. K., & Jamoussi, (1998). [Free radicals and antioxidants: physiology, human pathology and therapeutic aspects (part II)]. Therapie, 53(4), 315-39.
  • Dovnik, A., et al., (2015). Treatment of vulvovaginal candidiasis: a review of the literature. Acta Dermatovenerol Alp Pannonica Adriat, 2015. 24(1): p. 5-7.
  • Jenkins, V., & Postlewaite, J. (1951). Coccidioidal meningitis: report of four cases with necropsy findings in three cases. Annals of internal medicine, 1951. 35(5), p. 1068-1084.
  • Webber, M. A., & Piddock, L. J. V. (2003). The importance of efflux pumps in bacterial antibiotic resistance. Journal of Antimicrobial Chemotherapy, 51(1), p. 9-11.
  • Touitou, E., et al., (2000). Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release, 65(3), 403-418.
  • Pandit, J. M., Garg, & Jain, N. K. (2014). Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection. Journal of Liposome Research, 24(2), 163-169.
  • Mittal, A. K., Chisti, Y., & Banerjee, U. C. (2013). Synthesis of metallic nanoparticles using plant extracts. Biotechnology Advances, 31(2), 346- 356.
  • Ling, X., et al., (2015). Synthesis and characterization of hyaluronic acid-platinum(iv) nanoconjugate with enhanced antitumor response and reduced adverse effects. RSC Advances, 5(99), p. 81668-81681.
  • Haghighi, F. Farahbakhsh, S.R.M., Eskandari, M. (2015). Evaluation of antifungal activity of ZnO/Ag nanoparticles on Candida albicans biofilm.
  • Ying Wang, P. L. R. (2016). Biodegradable functional polycarbonate micells for Controlled release of amphotericin B. Acta Biomaterialia,
  • eemu, J. N. P. K. (1998). Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clinical Pharmacology & Therapeutics, 63(3), 332-341.
  • Viswanad, L. T. (2012). Formulation and optimization of clotrimazole - loaded proniosomal gel. Scientia Pharmaceutica,
  • Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54, S131-S155.
  • Galloway, J. W., Keijser, B. J., & Williams, D. M. (2016). Saliva in studies of epidemiology of human disease: the UK B iobank project. Periodontology 2000, 70(1), p. 184-195.
  • Webber, M. A., & Piddock, L. J. V. (2003). The importance of efflux pumps in bacterial antibiotic resistance. Journal of Antimicrobial Chemotherapy, 51(1), 9-11.
  • Zotchev, S. B. (2003 ). Polyene macrolide antibiotics and their applications in human therapy. Curr Med Chem, 10(3), 211-23.
  • Rhoads, J. L. et al., (1987). Chronic vaginal candidiasis in women with human immunodeficiency virus infection . JAMA, 257(22), 3105-3107.
  • Joshi, M., & Patravale, V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. International Journal of Pharmaceutics, 346(1), 124-132.
  • Haghighi, S. R. M., Farahbakhsh, E., & Eskandari, M. (2015). Evaluation of antifungal activity of ZnO/Ag nanoparticles on Candida albicans biofilm.
  • Ying Wang, P. L. R. (2016). Biodegradable functional polycarbonate micells for Controlled release of amphotericin B. Acta Biomaterialia,
  • Desai, S. (2011). Development and evaluation of niosomal antifungal. IJPS, 2011.
  • Viswanad, L. T. (2012). Formulation and optimization of clotrimazole - loaded proniosomal gel. Scientia Pharmaceutica,
  • Teemu, J. N. P. K. (1998). Simvastatin but not pravastatin is very susceptible tointeraction with the CYP3A4 inhibitor itraconazole. Clinical Pharmacology & Therapeutics, 63(3), 332-341.
  • Liangti Qu, L. D. A. E. O. (2006). Shape/Size- Controlled Syntheses of Metal Nanoparticles for Site-Selective Modification of Carbon Nanotubes. JACS,

Cite this article

APA

    APA : Arshad, S., Khan, R. A., & Sadia, H. (2021). Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine. Global Pharmaceutical Sciences Review, VI(I), 55-60. https://doi.org/10.31703/gpsr.2021(VI-I).06

CHICAGO

    CHICAGO : Arshad, Salman, Rabia Arshad Khan, and Haleema Sadia. 2021. "Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine." Global Pharmaceutical Sciences Review, VI (I): 55-60 doi: 10.31703/gpsr.2021(VI-I).06

HARVARD

    HARVARD : ARSHAD, S., KHAN, R. A. & SADIA, H. 2021. Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine. Global Pharmaceutical Sciences Review, VI, 55-60.

MHRA

    MHRA : Arshad, Salman, Rabia Arshad Khan, and Haleema Sadia. 2021. "Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine." Global Pharmaceutical Sciences Review, VI: 55-60

MLA

    MLA : Arshad, Salman, Rabia Arshad Khan, and Haleema Sadia. "Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine." Global Pharmaceutical Sciences Review, VI.I (2021): 55-60 Print.

OXFORD

    OXFORD : Arshad, Salman, Khan, Rabia Arshad, and Sadia, Haleema (2021), "Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine", Global Pharmaceutical Sciences Review, VI (I), 55-60

TURABIAN

    TURABIAN : Arshad, Salman, Rabia Arshad Khan, and Haleema Sadia. "Responding to the Hitch in Fighting Candida Albicans Through Nanomedicine." Global Pharmaceutical Sciences Review VI, no. I (2021): 55-60. https://doi.org/10.31703/gpsr.2021(VI-I).06